S1418 Pembrolizumab in Treating Patients With Triple-Negative Breast Cancer - Mercy Medical Center

S1418 Pembrolizumab in Treating Patients With Triple-Negative Breast Cancer

Posted on: January 1, 2020

This randomized phase III trial studies how well pembrolizumab works in treating triple-negative breast cancer. Monoclonal antibodies, such as may interfere with the ability of tumor cells to grow and spread. Eligibility includes being at least 18 years old and patients must have histologically confirmed estrogen receptor (ER)-, progesterone receptor (PR)- and HER2-negative (triple-negative, TNBC) with residual invasive breast cancer after completion of neoadjuvant chemotherapy; residual disease must be >= 1 cm in greatest dimension, and/or have positive lymph nodes (ypN+) observed on pathologic exam and no metastatic disease. Call Mercy clinical trials for further eligibility criteria.

Leave a Reply

Mercy Medical Center | 1320 Mercy Drive NW, Canton, OH 44708 | info@cantonmercy.org
Contact Us | Careers | Privacy Policy | Copyright © 2017 Mercy Medical Center